indigestion with glp 1 from GLP-1 Injections What Are GLP-1 Medications? A

Acknowledgements The authors thank Michael Bonar, Creative Director at the Leicester Diabetes Centre, for the original figure concept

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns

Ask whether there's a clinical team contact separate from general customer support for medical questions post-shipment

Any decision to initiate GLP-1 therapy should involve shared decision-making that weighs individual patient factors, comorbidities, and realistic expectations about potential cognitive benefits